{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T23:15:56Z","timestamp":1740179756477,"version":"3.37.3"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,9,4]],"date-time":"2024-09-04T00:00:00Z","timestamp":1725408000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,9,4]],"date-time":"2024-09-04T00:00:00Z","timestamp":1725408000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["npj Digit. Med."],"DOI":"10.1038\/s41746-024-01211-8","type":"journal-article","created":{"date-parts":[[2024,9,4]],"date-time":"2024-09-04T07:03:12Z","timestamp":1725433392000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Regulatory considerations for developing remote measurement technologies for Alzheimer\u2019s disease research"],"prefix":"10.1038","volume":"7","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4677-2914","authenticated-orcid":false,"given":"G\u00fcl","family":"Erdemli","sequence":"first","affiliation":[]},{"given":"Margarita","family":"Grammatikopoulou","sequence":"additional","affiliation":[]},{"given":"Bertil","family":"Wagner","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7975-8436","authenticated-orcid":false,"given":"Srinivasan","family":"Vairavan","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9647-5972","authenticated-orcid":false,"given":"Jelena","family":"Curcic","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6314-216X","authenticated-orcid":false,"given":"Dag","family":"Aarsland","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0009-0004-4299-5138","authenticated-orcid":false,"given":"Gayle","family":"Wittenberg","sequence":"additional","affiliation":[]},{"given":"Spiros","family":"Nikolopoulos","sequence":"additional","affiliation":[]},{"given":"Marijn","family":"Muurling","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5328-1243","authenticated-orcid":false,"given":"Holger","family":"Froehlich","sequence":"additional","affiliation":[]},{"given":"Casper","family":"de Boer","sequence":"additional","affiliation":[]},{"given":"Niraj M.","family":"Shanbhag","sequence":"additional","affiliation":[]},{"given":"Vera J. M.","family":"Nies","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0791-7543","authenticated-orcid":false,"given":"Neva","family":"Coello","sequence":"additional","affiliation":[]},{"given":"Dianne","family":"Gove","sequence":"additional","affiliation":[]},{"given":"Ana","family":"Diaz","sequence":"additional","affiliation":[]},{"given":"Suzanne","family":"Foy","sequence":"additional","affiliation":[]},{"given":"Wim","family":"Dartee","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0295-6834","authenticated-orcid":false,"given":"Anna-Katharine","family":"Brem","sequence":"additional","affiliation":[]}],"member":"297","published-online":{"date-parts":[[2024,9,4]]},"reference":[{"key":"1211_CR1","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1186\/s13024-019-0333-5","volume":"14","author":"MA DeTure","year":"2019","unstructured":"DeTure, M. A. & Dickson, D. W. The neuropathological diagnosis of Alzheimer\u2019s disease. Mol. Neurodegener. 14, 32 (2019).","journal-title":"Mol. Neurodegener."},{"key":"1211_CR2","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1016\/j.jalz.2016.02.002","volume":"12","author":"B Dubois","year":"2016","unstructured":"Dubois, B. et al. Preclinical Alzheimer\u2019s disease: definition, natural history, and diagnostic criteria. Alzheimers Dement. 12, 292\u2013323 (2016).","journal-title":"Alzheimers Dement."},{"key":"1211_CR3","doi-asserted-by":"publisher","first-page":"e12785","DOI":"10.2196\/12785","volume":"21","author":"A Piau","year":"2019","unstructured":"Piau, A., Wild, K., Mattek, N. & Kaye, J. Current state of digital biomarker technologies for real-life, home-based monitoring of cognitive function for mild cognitive impairment to mild Alzheimer disease and implications for clinical care: systematic review. J. Med. Internet Res. 21, e12785 (2019).","journal-title":"J. Med. Internet Res."},{"key":"1211_CR4","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2023.1210974","volume":"14","author":"AK Brem","year":"2023","unstructured":"Brem, A. K. et al. Digital endpoints in clinical trials of Alzheimer\u2019s disease and other neurodegenerative diseases: challenges and opportunities. Front Neurol. 14, 1210974 (2023).","journal-title":"Front Neurol."},{"key":"1211_CR5","first-page":"513","volume":"8","author":"J Kaye","year":"2021","unstructured":"Kaye, J. et al. Using digital tools to advance Alzheimer\u2019s drug trials during a pandemic: The EU\/US CTAD Task Force. J. Prev. Alzheimers Dis. 8, 513\u2013519 (2021).","journal-title":"J. Prev. Alzheimers Dis."},{"key":"1211_CR6","unstructured":"European Medicines Agency Questions and answers: Qualification of digital technology-based methodologies to support approval of medicinal products (EMA\/219860\/2020). (2020). https:\/\/www.ema.europa.eu\/en\/documents\/other\/questions-answers-qualification-digital-technology-based-methodologies-support-approval-medicinal_en.pdf. Accessed 10 January 2024."},{"key":"1211_CR7","unstructured":"FDA Framework for the Use of Digital Health Technologies in Drug and Biological Product Development. (2023) https:\/\/www.fda.gov\/media\/166396\/download?attachment. Accessed 10 January 2024."},{"key":"1211_CR8","doi-asserted-by":"publisher","first-page":"619513","DOI":"10.3389\/fmed.2021.619513","volume":"8","author":"MJHJ Dekker","year":"2021","unstructured":"Dekker, M. J. H. J., Stolk, P. & Pasmooij, A. M. G. The use of remote monitoring technologies: a review of recent regulatory scientific advices, qualification opinions, and qualification advices issued by the European Medicines Agency. Front Med. (Lausanne). 8, 619513 (2021).","journal-title":"Front Med. (Lausanne)."},{"key":"1211_CR9","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1159\/000517411","volume":"5","author":"L Servais","year":"2021","unstructured":"Servais, L. et al. First regulatory qualification of a novel digital endpoint in Duchenne muscular dystrophy: a multi-stakeholder perspective on the impact for patients and for drug development in neuromuscular diseases. Digit Biomark. 5, 183\u2013190 (2021).","journal-title":"Digit Biomark."},{"key":"1211_CR10","doi-asserted-by":"publisher","first-page":"2391","DOI":"10.1038\/s41591-023-02459-5","volume":"29","author":"L Servais","year":"2023","unstructured":"Servais, L. et al. First regulatory qualification of a digital primary endpoint to measure treatment efficacy in DMD. Nat. Med. 29, 2391\u20132392 (2023).","journal-title":"Nat. Med."},{"key":"1211_CR11","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1038\/s41746-023-00886-9","volume":"6","author":"A Bertha","year":"2023","unstructured":"Bertha, A. et al. Incorporating digitally derived endpoints within clinical development programs by leveraging prior work. NPJ Digit Med. 6, 139 (2023).","journal-title":"NPJ Digit Med."},{"key":"1211_CR12","doi-asserted-by":"publisher","first-page":"5920","DOI":"10.3390\/s20205920","volume":"20","author":"M Viceconti","year":"2020","unstructured":"Viceconti, M. et al. Toward a regulatory qualification of real-world mobility performance biomarkers in Parkinson\u2019s patients using digital mobility outcomes. Sensors 20, 5920 (2020).","journal-title":"Sensors"},{"key":"1211_CR13","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2022.996903","volume":"9","author":"M Viceconti","year":"2022","unstructured":"Viceconti, M. et al. On the use of wearable sensors as mobility biomarkers in the marketing authorization of new drugs: a regulatory perspective. Front Med. 9, 996903 (2022).","journal-title":"Front Med."},{"key":"1211_CR14","first-page":"1133","volume":"2022","author":"L Chen","year":"2022","unstructured":"Chen, L. et al. Fatigue and sleep assessment using digital sleep trackers: insights from a multi-device pilot study. Annu. Int. Conf. IEEE Eng. Med Biol. Soc. 2022, 1133\u20131136 (2022).","journal-title":"Annu. Int. Conf. IEEE Eng. Med Biol. Soc."},{"key":"1211_CR15","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1159\/000512513","volume":"4","author":"L Rochester","year":"2020","unstructured":"Rochester, L. et al. A roadmap to inform development, validation and approval of digital mobility outcomes: the mobilise-D approach. Digit Biomark. 4, 13\u201327 (2020).","journal-title":"Digit Biomark."},{"key":"1211_CR16","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1186\/s13195-021-00825-4","volume":"13","author":"M Muurling","year":"2021","unstructured":"Muurling, M. et al. Remote monitoring technologies in Alzheimer\u2019s disease: design of the RADAR-AD study. Alzheimers Res. Ther. 13, 89 (2021).","journal-title":"Alzheimers Res. Ther."},{"key":"1211_CR17","unstructured":"Guideline on the clinical investigation of medicines for the treatment of Alzheimer\u2019s disease. (2018) CPMP\/EWP\/553\/95 Rev.2. https:\/\/www.ema.europa.eu\/en\/clinical-investigation-medicines-treatment-alzheimers-disease-scientific-guideline. Accessed 2 June 2024."},{"key":"1211_CR18","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/j.trci.2018.01.003","volume":"4","author":"S Weintraub","year":"2018","unstructured":"Weintraub, S. et al. Measuring cognition and function in the preclinical stage of Alzheimer\u2019s disease. Alzheimers Dement (N.Y). 4, 64\u201375 (2018).","journal-title":"Alzheimers Dement (N.Y)."},{"key":"1211_CR19","doi-asserted-by":"crossref","unstructured":"Bertens, D. et al. The effect of diagnostic criteria on outcome measures in preclinical and prodromal Alzheimer\u2019s disease: implications for trial design. Alzheimers Dement (N. Y.) 3(4), 513\u2013523 (2017).","DOI":"10.1016\/j.trci.2017.08.005"},{"issue":"6","key":"1211_CR20","doi-asserted-by":"publisher","first-page":"1145","DOI":"10.1002\/ana.26071","volume":"89","author":"RC Petersen","year":"2021","unstructured":"Petersen, R. C. et al. NIA-AA Alzheimer\u2019s disease framework: clinical characterization of stages. Ann. Neurol. 89(6), 1145\u20131156 (2021).","journal-title":"Ann. Neurol."},{"key":"1211_CR21","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1159\/000509725","volume":"4","author":"C Manta","year":"2020","unstructured":"Manta, C., Patrick-Lake, B. & Goldsack, J. C. Digital measures that matter to patients: a framework to guide the selection and development of digital measures of health. Digit Biomark. 4, 69\u201377 (2020).","journal-title":"Digit Biomark."},{"key":"1211_CR22","doi-asserted-by":"publisher","DOI":"10.3389\/fnagi.2021.643135","volume":"13","author":"TG Stavropoulos","year":"2021","unstructured":"Stavropoulos, T. G. et al. Wearable devices for assessing function in Alzheimer\u2019s Disease: a European public involvement activity about the features and preferences of patients and caregivers. Front Aging Neurosci. 13, 643135 (2021).","journal-title":"Front Aging Neurosci."},{"key":"1211_CR23","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2020.582207","volume":"11","author":"AP Owens","year":"2020","unstructured":"Owens, A. P. et al. Selecting remote measurement technologies to optimize assessment of function in early Alzheimer\u2019s disease: a case study. Front Psychiatry 11, 582207 (2020).","journal-title":"Front Psychiatry"},{"key":"1211_CR24","doi-asserted-by":"publisher","first-page":"2826","DOI":"10.3390\/s20102826","volume":"20","author":"TG Stavropoulos","year":"2020","unstructured":"Stavropoulos, T. G., Papastergiou, A., Mpaltadoros, L., Nikolopoulos, S. & Kompatsiaris, I. IoT wearable sensors and devices in elderly care: a literature review. Sensors 20, 2826 (2020).","journal-title":"Sensors"},{"key":"1211_CR25","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1038\/s41746-023-00978-6","volume":"6","author":"M Muurling","year":"2023","unstructured":"Muurling, M. et al. Augmented reality versus standard tests to assess cognition and function in early Alzheimer\u2019s disease. NJP Digit. Med. 6, 234 (2023).","journal-title":"NJP Digit. Med."},{"key":"1211_CR26","unstructured":"Lentzen, M. et al. Assessment of RMTs for Discriminating Stages of Alzheimer\u2019s Disease. Poster presented at the Alzheimer\u2019s Association International Conference, 16-20 July 2023, Amsterdam, The Netherlands. https:\/\/alz.confex.com\/alz\/2023\/meetingapp.cgi\/Paper\/76856. Accessed 10 January 2024."},{"key":"1211_CR27","unstructured":"Vairavan, S. et al. A multimodal digital biomarker of functional deficits in early-stage Alzheimer\u2019s disease: Results of the RADAR-AD study. Poster presented at the Alzheimer\u2019s Association International Conference, 16-20 July 2023, Amsterdam, The Netherlands. https:\/\/alz.confex.com\/alz\/2023\/meetingapp.cgi\/Paper\/71136. Accessed 10 January 2024."},{"key":"1211_CR28","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1007\/s43441-023-00535-z","volume":"57","author":"L Gelis","year":"2023","unstructured":"Gelis, L. et al. Digital tools-regulatory considerations for application in clinical trials. Ther. Innov. Regul. Sci. 57, 769\u2013782 (2023).","journal-title":"Ther. Innov. Regul. Sci."},{"key":"1211_CR29","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1038\/s41746-023-00790-2","volume":"6","author":"S Colloud","year":"2023","unstructured":"Colloud, S. et al. Evolving regulatory perspectives on digital health technologies for medicinal product development. NJP Digit. Med. 6, 56 (2023).","journal-title":"NJP Digit. Med."},{"key":"1211_CR30","unstructured":"EMA Regulatory Science to 2025: strategic reflection. EMA\/110706\/2020. (2020) https:\/\/www.ema.europa.eu\/en\/documents\/regulatory-procedural-guideline\/ema-regulatory-science-2025-strategic-reflection_en.pdf. Accessed 10 January 2024."}],"container-title":["npj Digital Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41746-024-01211-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41746-024-01211-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41746-024-01211-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,4]],"date-time":"2024-09-04T07:07:19Z","timestamp":1725433639000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41746-024-01211-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,4]]},"references-count":30,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["1211"],"URL":"https:\/\/doi.org\/10.1038\/s41746-024-01211-8","relation":{},"ISSN":["2398-6352"],"issn-type":[{"type":"electronic","value":"2398-6352"}],"subject":[],"published":{"date-parts":[[2024,9,4]]},"assertion":[{"value":"13 February 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 August 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 September 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"G.E., N.C., J.C., and W.D. are employees of Novartis and may hold shares in the company but have no non-financial competing interests. B.W., S.V., G.W., and S.F. are employees of Janssen Research & Development, LLC, a Johnson & Johnson company, and may hold stock options or shares in the company but have no non-financial competing interests. N.M.S. is an employee of Takeda and holds shares in the company but has no non-financial competing interests. D.A. has received research support and\/or honoraria from Astra-Zeneca, H. Lundbeck, Novartis Pharmaceuticals, Biogen, and GE Health, and served as a paid consultant for H. Lundbeck, Eisai, Heptares, Mentis Cura, and Roche Diagnostics, but declares no non-financial competing interests. H.F. has received research support from UCB Pharma and AbbVie GmbH & Co KG. All other authors declare no financial or non-financial competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"232"}}